Plain-English translation of NCT07553663 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a medication called in people with metabolic dysfunction-associated steatohepatitis (MASH)—a serious condition where fat builds up in the liver and causes inflammation. Researchers want to understand how the medication moves through your body and whether it's safe to use in patients with this condition.
Fatty liver disease is becoming increasingly common in people with diabetes, high blood pressure, and obesity, but there are limited treatment options available. This study is exploring whether this medication could offer a new way to help reduce liver damage in these patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll have screening visits over about 4 weeks to make sure you qualify. Then you'll receive a single 60-milligram dose of the medication. You'll stay for observation for about 4 days after receiving the dose, and then return for follow-up visits over the next 24 days so researchers can check how your body is handling the medication and watch for any side effects. The entire study lasts about 8 weeks.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Corcept Therapeutics
Enrollment target
~15 participants
Started
April 2026
Primary completion
October 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eric Lawitz, MD
Corcept Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.